Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PerFoam is a topical foam formulation containing 5% permethrin, a synthetic pyrethroid neurotoxin. It is primarily indicated for the treatment of scabies, an infestation caused by the mite *Sarcoptes scabiei*. Permethrin acts by binding to voltage-gated sodium channels on the nerve cell membranes of the parasites, preventing the inactivation of these channels. This leads to prolonged sodium current, delayed repolarization, and stable depolarization of the nerve membrane, resulting in paralysis and eventual death of the mites. Developed by PruGen Pharmaceuticals, the foam delivery system was designed to provide a more cosmetically elegant and easily applied alternative to traditional 5% permethrin creams, potentially improving patient adherence and coverage for widespread infestations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PerFoam.